4D Molecular Therapeutics, Inc.FDMTNASDAQ
LOADING
|||
R&D Expense Growth Under Pressure
Trending lower, below historical average.
Left:
||||
Year-over-year research & development expense growth
Latest
3.10%
↓ 67% below average
Average (30q)
9.30%
Historical baseline
Range
High:67.27%
Low:-26.49%
Volatility
1008.3%
High variability
| Period | Value |
|---|---|
| Q3 2025 | 3.10% |
| Q2 2025 | 17.82% |
| Q1 2025 | -5.54% |
| Q4 2024 | 11.96% |
| Q3 2024 | 20.79% |
| Q2 2024 | 14.32% |
| Q1 2024 | 7.08% |
| Q4 2023 | 3.84% |
| Q3 2023 | 6.28% |
| Q2 2023 | 5.23% |
| Q1 2023 | 4.24% |
| Q4 2022 | 13.52% |
| Q3 2022 | -7.26% |
| Q2 2022 | 5.37% |
| Q1 2022 | 10.57% |
| Q4 2021 | 10.66% |
| Q3 2021 | 4.05% |
| Q2 2021 | 19.22% |
| Q1 2021 | 1.30% |
| Q4 2020 | 9.09% |
| Q3 2020 | -26.49% |
| Q2 2020 | 19.47% |
| Q1 2020 | 6.46% |
| Q4 2019 | 31.84% |
| Q3 2019 | 10.38% |
| Q2 2019 | 0.00% |
| Q1 2019 | 67.27% |
| Q4 2018 | 0.00% |
| Q3 2018 | 23.71% |
| Q2 2018 | 0.00% |
| Q1 2018 | 0.00% |